Norcliffe Capital

Norcliffe Capital is a London-based venture capital firm founded in 2018 that directly invests in early-stage UK life science and disruptive technology companies with high growth potential. It focuses on seed, pre-Series A and Series A rounds and seeks tax-efficient investments within these sectors.

Patricia Reynolds

Founder, CEO and Director

8 past transactions

Dxcover

Venture Round in 2025
Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Oxford Endovascular

Series A in 2024
Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.

Glen Clova Scientific

Seed Round in 2024
Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to form natural antibodies against harmful targets. The company's innovative approach enhances the quality of treatment for chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. This not only helps to lower the overall cost of treatment for patients but also expands access to healthcare in markets with limited infrastructure. Through its advancements in biologic drug development, Glen Clova Scientific seeks to improve patient outcomes and provide effective therapeutic options.

SMi Systems

Seed Round in 2023
SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

Dxcover

Series A in 2023
Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Aureum Diagnostics

Venture Round in 2023
Aureum Diagnostics develops and manufactures point-of-care diagnostic platforms and medical equipment. Its core product is an electrochemical sensor-based tool designed for rapid, sensitive detection of COVID-19 and other life-threatening conditions.

Biosceptre

Venture Round in 2021
Biosceptre International Limited is a biopharmaceutical company based in Babraham, United Kingdom, focused on researching and developing innovative antibody products targeting the nf-P2X7 receptor for cancer treatment. Established in 2013, the company creates polyclonal antibodies aimed at treating various forms of skin cancer, including basal cell carcinoma and advanced basal cell carcinoma, as well as developing systemic antibodies for a range of tumors. Additionally, Biosceptre is advancing a therapeutic anti-cancer vaccine and is involved in the development of chimeric antigen receptor T-cell therapy. By employing multiple modalities, including systemic antibodies and vaccines, the company aims to provide effective therapeutic options for cancer patients globally.

Dxcover

Seed Round in 2021
Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.